Citation: | LUO Gu-po, ZENG Xi, CAO Han-yu, et al. The Clinical Significance of HPV L1/PD-L1 Tests Combined with Colposcopy for Cervical Precancerous Lesions and Cervical Cancer[J]. Journal of Sichuan University (Medical Sciences), 2021, 52(3): 516-522. DOI: 10.12182/20210560105 |
[1] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2018,68(6): 394–424. DOI: 10.3322/caac.21492
|
[2] |
BOSCH F X, LORINCZ A, MUNOZ N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol,2002,55(4): 244–265. DOI: 10.1136/jcp.55.4.244
|
[3] |
陈惠祯, 蔡红兵. 子宫颈癌、子宫内膜癌、卵巢上皮癌手术方式的选择. 恩施: 第23届湖北省肿瘤学术大会, 2013.
|
[4] |
FENG Y C, ZHANG Y, LIU C M, et al. Increased HPV L1 gene methylation and multiple infection status lead to the difference of cervical epithelial cell lesion in different ethnic women of Xinjiang, China. Medicine (Baltimore), 2017, 96(12): e6409[2020-04-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371478/. doi: 10.1097/MD.0000000000006409.
|
[5] |
SUN C, MEZZADRA R, SCHUMACHER T N. Regulation and function of the PD-L1 checkpoint. Immunity,2018,48(3): 434–452. DOI: 10.1016/j.immuni.2018.03.014
|
[6] |
HANSEN J D, DU PASQUIER L, LEFRANC M P, et al. The B7 family of immunoregulatory receptors: A comparative and evolutionary perspective. Mol Immunol,2009,46(3): 457–472. DOI: 10.1016/j.molimm.2008.10.007
|
[7] |
MENG Y, LIANG H, HU J, et al. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer,2018,9(16): 2938–2945. DOI: 10.7150/jca.22532
|
[8] |
COBUCCI R, MAISONNETTE M, MACEDO E, et al. Pap test accuracy and severity of squamous intraepithelial lesion. Indian J Cancer,2016,53(1): 74–76. DOI: 10.4103/0019-509X.180825
|
[9] |
DIGGS L P, HSUEH E C. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res, 2017, 5: 12[2020-04-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353958/. doi: 10.1186/s40364-017-0093-8.
|
[10] |
SAHASRABUDDHE V V, PARHAM G P, MWANAHAMUNTU M H, et al. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res (Phila),2012,5(1): 11–17. DOI: 10.1158/1940-6207.CAPR-11-0540
|
[11] |
NAYAR R, WILBUR D C. The Pap test and Bethesda 2014. Cancer Cytopathol,2015,123(5): 271–281. DOI: 10.1002/cncy.21521
|
[12] |
TJALMA W A, DEPUYDT C E. Cervical cancer screening: which HPV test should be used—L1 or E6/E7? Eur J Obstet Gynecol Reprod Biol,2013,170(1): 45–46. DOI: 10.1016/j.ejogrb.2013.06.027
|
[13] |
LEE H, LEE K J, JUNG C K, et al. Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol,2008,36(12): 864–867. DOI: 10.1002/dc.20922
|
[14] |
YOSHIDA T, SANO T, KANUMA T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer,2008,114(2): 83–88. DOI: 10.1002/cncr.23366
|
[15] |
黄 斌, 李瑞珍, 刘志红, 等. HPV L1壳蛋白在宫颈脱落细胞中的表达及临床意义. 华中科技大学学报(医学版),2009,38(6): 824–828.
|
[16] |
SADREDDINI S, BARADARAN B, AGHEBATI-MALEKI A, et al. Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol,2019,234(6): 8541–8549. DOI: 10.1002/jcp.27816
|
[17] |
AKINLEYE A, RASOOL Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol,2019,12: 92[2020-04-03]. https://doi.org/10.1186/s13045-019-0779-5.
|
[18] |
VINCENT-FABERT C, ROLAND L, ZIMBER-STROBL U, et al. Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-kappaB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma. Cell Commun Signal,2019,17: 89[2020-04-03]. https://doi.org/10.1186/s12964-019-0391-x.
|
[19] |
LOHARAMTAWEETHONG K, SUPAKATITHAM C, VINYUVAT S, et al. Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer. Asian Pac J Allergy Immunol, 2020, 12: 1758835920963001[2020-04-01]. https://doi.org/10.1177/1758835920963001.
|
[20] |
XU-MONETTE Z Y, ZHANG M, LI J, et al. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol, 2017, 8: 1597[2020-04-01]. https://doi.org/10.3389/fimmu.2017.01597.
|
[21] |
YANG W, LU Y P, YANG Y Z, et al. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res,2017,43(10): 1602–1612. DOI: 10.1111/jog.13411
|
[22] |
REDDY O L, SHINTAKU P I, MOATAMED N A. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol,2017,12: 45[2020-04-03]. https://doi.org/10.1186/s13000-017-0631-6.
|
[23] |
曹泽毅. 子宫颈癌. 北京: 人民卫生出版社, 2017: 169-204.
|